Role of gemcitabine in breast cancer management: An update

Seminars in Oncology

Volumn 33, Issue SUPPL. 2, 2006, Pages 6-14

  Wirk, Baldeep ^a   Perez, Edith ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ASPARTATE AMINOTRANSFERASE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GEMCITABINE; NAVELBINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALOPECIA; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DNA DAMAGE; DNA REPAIR; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HUMAN; LEUKOPENIA; LIVER FUNCTION TEST; LIVER TOXICITY; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PRIMARY HEALTH CARE; PRIORITY JOURNAL; REFRACTORY PERIOD; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 32044433992     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.07.028     Document Type: Conference Paper

References (53)

1. P. Huang, S. Chubb, L.W. Hertel Action of 2',2'-difluorodeoxycytidine on DNA synthesis Cancer Res 51 1991 6110 6117
2. M. Blackstein, C.L. Vogel, R. Ambinder Gemcitabine as first-line therapy in patients with metastatic breast cancer A phase II trial Oncology 62 2002 2 8
3. T. Brodowicz, W.J. Kostler, R. Moslinger Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer Breast 9 2000 338 342
4. J. Carmichael, K. Possinger, P. Phillip Advanced breast cancer A phase II trial with gemcitabine J Clin Oncol 13 1995 2731 2736
5. M. Spielmann, A. Llombart-Cussac, S. Kalla Single-agent gemcitabine is active in previously treated metastatic breast cancer Oncology 60 2001 303 307
6. K. Possinger, M. Kaufmann, R. Coleman Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer Anticancer Drugs 10 1999 155 162
7. P. Schmid, K. Akrivakis, B. Flath Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer Anticancer Drugs 10 1999 625 631
8. M. Martin Platinum compounds in the treatment of advanced breast cancer Clin Breast Cancer 2 2001 190 208
9. C.J. van Moorsel, G. Veerman, A.M. Bergman Combination chemotherapy studies with gemcitabine Semin Oncol 24 1997 S7-17-S7-23
10. G. Achanta, H. Pelicano, L. Feng Interaction of p53 and DNA-PK in response to nucleoside analogues Potential role as a sensor complex for DNA damage Cancer Res 61 2001 8723 8729
11. R.A. Nagourney, J.S. Link, J.B. Blitzer Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients J Clin Oncol 18 2000 2245 2249
12. P.A. Burch, J.A. Mailliard, D.W. Hillman Phase II study of gemcitabine and cisplatin in patients with metastatic breast cancer A North Central Cancer Treatment Group Trial Am J Clin Oncol 28 2005 195 200
13. S. Fcps, Z. Alauddin, E. Rehman Gemcitabine and cisplatin combination chemotherapy as second-line treatment in patients with metastatic breast cancer Proc Am Soc Clin Oncol 22 2003 53 (abstr 212)
14. B. Xu, K. Li, D. Liu Phase II trial of gemcitabine and cisplatin in anthracycline-resistant metastatic breast cancer Proc Am Soc Clin Oncol 22 2003 53 (abstr 211)
15. F.L. Nasr, G.Y. Chahine, J.G. Kattan Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer Clin Breast Cancer 5 2004 117 122
16. S. Binet, E. Chaineau, A. Fellous Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules Int J Cancer 46 1990 262 266
17. P. Fumoleau, F.M. Delgado, T. Delozier Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy J Clin Oncol 11 1993 1245 1252
18. A. Romero, M.G. Rabinovich, C.T. Vallejo Vinorelbine as first-line chemotherapy for metastatic breast carcinoma J Clin Oncol 12 1994 36 41
19. G. Gasparini, O. Caffo, S. Barni Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients A phase II study J Clin Oncol 12 1994 2094 2101
20. K. Haider, G.V. Kornek, W. Kwasny Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor Breast Cancer Res Treat 55 1999 203 211
21. R. Valenza, V. Leonardi, V. Gebbia Gemcitabine and vinorelbine in pretreated advanced breast cancer A pilot study Ann Oncol 11 2000 495 496
22. G.P. Stathopoulos, S.K. Rigatos, N. Pergantas Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer J Clin Oncol 20 2002 37 41
23. C. Nicolaides, M.A. Dimopoulos, E. Samantas Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy A phase II study conducted by the Hellenic Cooperative Oncology Group Ann Oncol 11 2000 873 875
24. M.C. Bissery Preclinical pharmacology of docetaxel Eur J Cancer 31A 1995 S1 S6 (suppl 4)
25. V. Valero Docetaxel as single-agent therapy in metastatic breast cancer Clinical efficacy Semin Oncol 24 1997 S13-11S-13-18
26. H.A. Burris 3rd Single-agent docetaxel (Taxotere) in randomized phase III trials Semin Oncol 26 1999 1 6
27. D. Mavroudis, N. Malamos, A. Alexopoulos Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine A multicenter phase II trial Greek Breast Cancer Cooperative Group. Ann Oncol 10 1999 211 215
28. G. Fountzilas, C. Nicolaides, D. Bafaloukos Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer A Hellenic Cooperative Oncology Group Phase II study Cancer Invest 18 2000 503 509
29. L.R. Laufman, C.H. Spiridonidis, J. Pritchard Monthly docetaxel and weekly gemcitabine in metastatic breast cancer A phase II trial Ann Oncol 12 2001 1259 1264
30. A. Alexopoulos, D. Tryfonopoulos, M.V. Karamouzis Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer Ann Oncol 15 2004 95 99
31. J.G. Chen, C.P. Yang, M. Cammer Gene expression and mitotic exit induced by microtubule-stabilizing drugs Cancer Res 63 2003 7891 7899
32. M. Clemons, M. Leahy, J. Valle Review of recent trials of chemotherapy for advanced breast cancer The taxanes Eur J Cancer 33 1997 2183 2193
33. A.D. Seidman, B.S. Reichman, J.P. Crown Paclitaxel as second and subsequent therapy for metastatic breast cancer Activity independent of prior anthracycline response J Clin Oncol 13 1995 1152 1159
34. A.M. Murad Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer Oncology (Huntingt) 17 2003 26 32
35. C. Delfino, G. Caccia, L.R. Gonzales Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer Oncology 66 2004 18 23
36. R. Paridaens, L. Biganzoli, P. Bruning Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer A European Organization for Research and Treatment of Cancer Randomized Study with cross-over J Clin Oncol 18 2000 724 733
37. K.S. Albain, S. Nag, G. Calderillo-Ruiz Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC) First report of overall survival Proc Am Soc Clin Oncol 22 2004 14S (abstr 510)
38. M.L. Rothenberg, A. Sharma, G.R. Weiss Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors Ann Oncol 9 1998 733 738
39. R. Colomer, A. Llombart-Cussac, A. Lluch Biweekly paclitaxel plus gemcitabine in advanced breast cancer Phase II trial and predictive value of HER2 extracellular domain Ann Oncol 15 2004 201 206
40. P. Vici, P. Foggi, E. Capomolla Biweekly paclitaxel/gemcitabine (P/G) as salvage treatment in breast cancer patients (pts) Preliminary results Proc Am Soc Clin Oncol 21 2002 61b (abstr 2054)
41. P.A. Garle, L. Calvo, J.I. Mayordomo Gemcitabine and docetaxel given every other week as first-line therapy for metastatic breast cancer (MBC) Final results of a phase II study conducted within the Breast Cancer Investigation Spanish Group (GEICAM) Proc Am Soc Clin Oncol 22 2003 50 (abstr 201)
42. D. Mavroudis, N. Malamos, A. Polyzos Breast Cancer Committee of the Hellenic Oncology Research Group (HORG) A multicenter phase II study of docetaxel plus gemcitabine biweekly administration as first-line treatment in patients with metastatic breast cancer (MBC) Proc Am Soc Clin Oncol 22 2003 65 (abstr 259)
43. G.V. Kornek, K. Haider, W. Kwasny Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor Clin Cancer Res 8 2002 1051 1056
44. A. Pelegr, L. Calvo, J.I. Mayordomo Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer Preliminary results from a phase II trial Semin Oncol 31 2004 20 24
45. J.A. O'Shaughnessy, S. Vukelja, T. Marsland Phase II trial of trastuzumab plus gemcitabine in chemotherapy-treated patients with metastic breast cancer Clin Breast Cancer 5 2004 142 147
46. R. Colomer, J.I. Mayordomo, L. Calvo Gemcitabine, paclitaxel plus trastuzumab (GTH) in HER2 ECD-positive metastatic breast cancer Proc Am Soc Clin Oncol 23 2004 61 (abstr 740)
47. A. Polyzos, D. Mavroudis, J. Boukovinas Breast Cancer Working Group A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) overexpressing HER-2 Proc Am Soc Clin Oncol 23 2004 58 (abstr 728)
48. E.A. Perez, C.L. Vogel, D.H. Irwin Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer J Clin Oncol 19 2001 4216 4223
49. A.D. Seidman, D. Berry, C. Cirrincione CALGB 9840 Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC J Clin Oncol 22 2004 14S (abstr 512)
50. K.-S. Khoo, M. Zaidi, V. Srimuninnimit Randomized phase II trial of three gemcitabine (GEM)-taxane combinations in metastatic breast cancer (MBC) J Clin Oncol 22 2004 14S (abstr 710)
51. J.L. Blum, M.A. Savin, G. Edelman Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel J Clin Oncol 22 2004 14S (abstr 543)
52. P.F. Conte, S. Donati, A. Gennari Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer A phase II study Br J Cancer 93 2005 406 441
53. C. Zielinski, S. Beslija, Z. Mrsic-Krmpotic Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer A Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase II trial J Clin Oncol 23 2005 1401 1408